Skip to main content
Erschienen in: Deutsche Dermatologie 7/2022

01.07.2022 | Psoriasis vulgaris | Fortbildung

Sonderformen der Psoriasis

Therapie meist off-label

verfasst von: Dr. med. Dietrich Barth

Erschienen in: Deutsche Dermatologie | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Auszug

Die Behandlung von Sonderformen der Psoriasis ist weitaus schwieriger als die des Plaque-Typs. Studiendaten hierzu sind oft heterogen und reichen nicht aus, um neue Indikationen etablierter Therapien zu begründen, die daher meist off-label erfolgen.
Literatur
1.
Zurück zum Zitat Mrowietz U et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10 Mrowietz U et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10
2.
Zurück zum Zitat Nast et al. Therapie der Psoriasis vulgaris. AWMF-Reg.-Nr. 013-001; 2021 Nast et al. Therapie der Psoriasis vulgaris. AWMF-Reg.-Nr. 013-001; 2021
3.
Zurück zum Zitat Bissonnette R et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J Eur Acad Dermatol Venereol 2014; 28: 1298-1305 Bissonnette R et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J Eur Acad Dermatol Venereol 2014; 28: 1298-1305
4.
Zurück zum Zitat Michaelsson G et al. The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking. J Am Acad Dermatol 2006; 54: 737-8 Michaelsson G et al. The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking. J Am Acad Dermatol 2006; 54: 737-8
5.
Zurück zum Zitat Hagforsen E et al. Expression of nicotinic receptors in the skin of patients with palmoplantar pustulosis. Br J Dermatol 2002; 146: 383-91 Hagforsen E et al. Expression of nicotinic receptors in the skin of patients with palmoplantar pustulosis. Br J Dermatol 2002; 146: 383-91
6.
Zurück zum Zitat Takahara M. Clinical outcome of tonsillectomy for palmoplantar pustulosis and etiological relationship between palmoplantar pustulosis and tonsils. Adv Otorhinolaryngol 2011; 72: 86-8 Takahara M. Clinical outcome of tonsillectomy for palmoplantar pustulosis and etiological relationship between palmoplantar pustulosis and tonsils. Adv Otorhinolaryngol 2011; 72: 86-8
7.
Zurück zum Zitat Pasch MC. Nail Psoriasis: A Review of Treatment Options. Drugs 2016; 76: 675-705 Pasch MC. Nail Psoriasis: A Review of Treatment Options. Drugs 2016; 76: 675-705
8.
Zurück zum Zitat Nakamura RC et al. Comparison of nail lacquer clobetasol efficacy at 0.05%, 1% and 8% in nail psoriasis treatment: prospective, controlled and randomized pilot study. An Bras Dermatol 2012; 87: 203-11 Nakamura RC et al. Comparison of nail lacquer clobetasol efficacy at 0.05%, 1% and 8% in nail psoriasis treatment: prospective, controlled and randomized pilot study. An Bras Dermatol 2012; 87: 203-11
9.
Zurück zum Zitat Rigopoulos D et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology 2009; 218: 338−41 Rigopoulos D et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology 2009; 218: 338−41
10.
Zurück zum Zitat Demirsoy EO et al. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study. J Drugs Dermatol 2013; 12: 1039-43 Demirsoy EO et al. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study. J Drugs Dermatol 2013; 12: 1039-43
11.
Zurück zum Zitat Gümüşel M et al. Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study. J Eur Acad Dermatol Venereol 2011; 25: 1080−4 Gümüşel M et al. Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study. J Eur Acad Dermatol Venereol 2011; 25: 1080−4
12.
Zurück zum Zitat Tosti A et al. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 2009; 145: 269−71 Tosti A et al. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 2009; 145: 269−71
13.
Zurück zum Zitat Rich P et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol 2016; 74: 134-42 Rich P et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol 2016; 74: 134-42
14.
Zurück zum Zitat Elewski BE et al. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. J Am Acad Dermatol 2018; 78: 90−9 Elewski BE et al. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. J Am Acad Dermatol 2018; 78: 90−9
15.
Zurück zum Zitat Rich P et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008; 58: 224−31 Rich P et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008; 58: 224−31
16.
Zurück zum Zitat Walsh JA et al. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial. Clinical Rheumatology 2018; 37: 3285−96 Walsh JA et al. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial. Clinical Rheumatology 2018; 37: 3285−96
17.
Zurück zum Zitat Reich K et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol 2019; 181: 954-66 Reich K et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol 2019; 181: 954-66
18.
Zurück zum Zitat Elewski B et al. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. J Dermatol Treat 2022; 33: 261−5 Elewski B et al. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. J Dermatol Treat 2022; 33: 261−5
19.
Zurück zum Zitat Wasel N et al. Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S). Dermatol Ther (Heidelb) 2020; 10: 663−70 Wasel N et al. Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S). Dermatol Ther (Heidelb) 2020; 10: 663−70
20.
Zurück zum Zitat Foley P et al. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Dermatol 2018; 154: 676−83 Foley P et al. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Dermatol 2018; 154: 676−83
21.
Zurück zum Zitat Kristensen LE et al. Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPsAKE 1. J Eur Acad Dermatol Venereol 2022; 36: e389−92 Kristensen LE et al. Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPsAKE 1. J Eur Acad Dermatol Venereol 2022; 36: e389−92
22.
Zurück zum Zitat Galluzzo M et al. Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis. J Clin Med 2022; 11: 2631 Galluzzo M et al. Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis. J Clin Med 2022; 11: 2631
23.
Zurück zum Zitat Yang EJ et al. The impact of genital psoriasis on quality of life: a systematic review. Psoriasis (Auckl) 2018; 8: 41−7 Yang EJ et al. The impact of genital psoriasis on quality of life: a systematic review. Psoriasis (Auckl) 2018; 8: 41−7
24.
Zurück zum Zitat Kreuter A et al. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol 2006; 142: 1138-43 Kreuter A et al. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol 2006; 142: 1138-43
25.
Zurück zum Zitat Dattola A et al. Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review. Dermatol Ther 2018; 31: e12728 Dattola A et al. Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review. Dermatol Ther 2018; 31: e12728
26.
Zurück zum Zitat Lebwohl M et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004; 51: 723-30 Lebwohl M et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004; 51: 723-30
27.
Zurück zum Zitat Gribetz C et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004; 51: 731-8 Gribetz C et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004; 51: 731-8
28.
Zurück zum Zitat Nisticò SP et al. Different applications of monochromatic excimer light in skin diseases. Photomed Laser Surg 2009; 27: 647−54 Nisticò SP et al. Different applications of monochromatic excimer light in skin diseases. Photomed Laser Surg 2009; 27: 647−54
29.
Zurück zum Zitat Gilbert E, Ward NL. Efficacy of botulinum neurotoxin type A for treating recalcitrant plaque psoriasis. J Drugs Dermatol 2014; 13: 1407−8 Gilbert E, Ward NL. Efficacy of botulinum neurotoxin type A for treating recalcitrant plaque psoriasis. J Drugs Dermatol 2014; 13: 1407−8
30.
Zurück zum Zitat Zanchi M et al. Botulinum toxin type-A for the treatment of inverse psoriasis. J Eur Acad Dermatol Venereol 2008; 22: 431−6 Zanchi M et al. Botulinum toxin type-A for the treatment of inverse psoriasis. J Eur Acad Dermatol Venereol 2008; 22: 431−6
31.
Zurück zum Zitat González C et al. Breaking paradigms in the treatment of psoriasis: Use of botulinum toxin for the treatment of plaque psoriasis. Dermatol Ther 2020; 33: e14319 González C et al. Breaking paradigms in the treatment of psoriasis: Use of botulinum toxin for the treatment of plaque psoriasis. Dermatol Ther 2020; 33: e14319
32.
Zurück zum Zitat Foureur N et al. Prospective aetiological study of diaper dermatitis in the elderly. Br J Dermatol 2006; 155: 941-6 Foureur N et al. Prospective aetiological study of diaper dermatitis in the elderly. Br J Dermatol 2006; 155: 941-6
33.
Zurück zum Zitat Noji S et al. Discovery of a Janus kinase inhibitor bearing a highly three-dimensional Spiro scaffold: JTE-052 (delgocitinib) as a new dermatological agent to treat inflammatory skin disorders. J Med Chem 2020; 63: 7163-85 Noji S et al. Discovery of a Janus kinase inhibitor bearing a highly three-dimensional Spiro scaffold: JTE-052 (delgocitinib) as a new dermatological agent to treat inflammatory skin disorders. J Med Chem 2020; 63: 7163-85
34.
Zurück zum Zitat Lebwohl MG et al. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. N Engl J Med 2021; 385: 2219−29 Lebwohl MG et al. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. N Engl J Med 2021; 385: 2219−29
35.
Zurück zum Zitat Kapila S et al. Vulvar psoriasis in adults and children: a clinical audit of 194 cases and review of the literature. J Low Genit Tract Dis 2012; 16: 364-71 Kapila S et al. Vulvar psoriasis in adults and children: a clinical audit of 194 cases and review of the literature. J Low Genit Tract Dis 2012; 16: 364-71
36.
Zurück zum Zitat Guglielmetti A et al. J. Inverse psoriasis involving genital skin folds: successful therapy with dapsone. Dermatol Ther 2012; 2: 15 Guglielmetti A et al. J. Inverse psoriasis involving genital skin folds: successful therapy with dapsone. Dermatol Ther 2012; 2: 15
37.
Zurück zum Zitat Tajalli M et al. Effective use of oral tofacitinib and phototherapy in a patient with concomitant alopecia areata, vitiligo, and plaque and inverse psoriasis. Clin Case Rep 2020; 8: 819-22 Tajalli M et al. Effective use of oral tofacitinib and phototherapy in a patient with concomitant alopecia areata, vitiligo, and plaque and inverse psoriasis. Clin Case Rep 2020; 8: 819-22
38.
Zurück zum Zitat Jese R et al. A case of inverse psoriasis successfully treated with adalimumab. Acta Dermatovenerol Alp Pannonica Adriat 2014; 23: 21−3 Jese R et al. A case of inverse psoriasis successfully treated with adalimumab. Acta Dermatovenerol Alp Pannonica Adriat 2014; 23: 21−3
39.
Zurück zum Zitat Campos MA et al. Inverse psoriasis treated with ustekinumab. BMJ Case Rep 2016; 2016:bcr2016215019 Campos MA et al. Inverse psoriasis treated with ustekinumab. BMJ Case Rep 2016; 2016:bcr2016215019
40.
Zurück zum Zitat Guenther G et al. Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial. Acta Derm Venereol 2020; 100: adv00006 Guenther G et al. Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial. Acta Derm Venereol 2020; 100: adv00006
41.
Zurück zum Zitat Cather JC et al. Ixekizumab provides greater improvement versus placebo on the impact of genital psoriasis on sexual activity for patients with moderate-to-severe genital psoriasis in a randomized, double-blind phase 3b clinical trial. AAD Annual Meeting 2018, P 5935 Cather JC et al. Ixekizumab provides greater improvement versus placebo on the impact of genital psoriasis on sexual activity for patients with moderate-to-severe genital psoriasis in a randomized, double-blind phase 3b clinical trial. AAD Annual Meeting 2018, P 5935
42.
Zurück zum Zitat Merola JF et al. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol 2016; 41: 486-89 Merola JF et al. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol 2016; 41: 486-89
43.
Zurück zum Zitat Patrizi A et al. Nail dystrophies, scalp and intergluteal/perianal psoriatic lesions: risk factors for psoriatic arthritis in mild skin psoriasis? G Ital Dermatol Venereol 2014; 149: 177−84 Patrizi A et al. Nail dystrophies, scalp and intergluteal/perianal psoriatic lesions: risk factors for psoriatic arthritis in mild skin psoriasis? G Ital Dermatol Venereol 2014; 149: 177−84
44.
Zurück zum Zitat Sampogna F et al. Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex. Acta Derm Venereol 2014; 94: 411-4 Sampogna F et al. Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex. Acta Derm Venereol 2014; 94: 411-4
45.
Zurück zum Zitat Schlager JG et al. Topical treatments for scalp psoriasis. Cochrane Database of Systematic Reviews 2016; 2: CD009687 Schlager JG et al. Topical treatments for scalp psoriasis. Cochrane Database of Systematic Reviews 2016; 2: CD009687
46.
Zurück zum Zitat Menter A et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010; 62: 114−35 Menter A et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010; 62: 114−35
47.
Zurück zum Zitat Chan CS et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009; 60: 962−71 Chan CS et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009; 60: 962−71
48.
Zurück zum Zitat Mrowietz U et al. Efficacy of dimethyl fumarate treatment for moderate-to-severe plaque psoriasis: presentation extracts from the 29th EADV virtual congress, 29-31 October 2020. Expert Rev Clin Immunol 2021; 17 (sup2): 1−11 Mrowietz U et al. Efficacy of dimethyl fumarate treatment for moderate-to-severe plaque psoriasis: presentation extracts from the 29th EADV virtual congress, 29-31 October 2020. Expert Rev Clin Immunol 2021; 17 (sup2): 1−11
49.
Zurück zum Zitat Papp K et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015; 73: 37-49 Papp K et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015; 73: 37-49
50.
Zurück zum Zitat Paul C et al. Efficacy and safety of apremilast, an oral phos- phodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized con- trolled trial (ESTEEM 2). Br J Dermatol 2015; 173: 1387−99 Paul C et al. Efficacy and safety of apremilast, an oral phos- phodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized con- trolled trial (ESTEEM 2). Br J Dermatol 2015; 173: 1387−99
51.
Zurück zum Zitat Fotiadou C et al. Scalp psoriasis and biologic agents: a retrospective, comparative study from a tertiary psoriasis referral centre. J Eur Acad Dermatol Venereol 2016; 30: 2091−6 Fotiadou C et al. Scalp psoriasis and biologic agents: a retrospective, comparative study from a tertiary psoriasis referral centre. J Eur Acad Dermatol Venereol 2016; 30: 2091−6
52.
Zurück zum Zitat Bagel J et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol 2017; 77: 667-74 Bagel J et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol 2017; 77: 667-74
53.
Zurück zum Zitat Kivelevitch D et al. Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas. Expert Opin Pharmacother 2018; 19: 561−75 Kivelevitch D et al. Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas. Expert Opin Pharmacother 2018; 19: 561−75
54.
Zurück zum Zitat Irmer ML et al. Psoriasis an besonderen Arealen. hautnah dermatologie 2020; 36 (6): 32−9 Irmer ML et al. Psoriasis an besonderen Arealen. hautnah dermatologie 2020; 36 (6): 32−9
55.
Zurück zum Zitat Blauvelt A et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017, 76: 405−17 Blauvelt A et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017, 76: 405−17
Metadaten
Titel
Sonderformen der Psoriasis
Therapie meist off-label
verfasst von
Dr. med. Dietrich Barth
Publikationsdatum
01.07.2022
Verlag
Springer Medizin
Erschienen in
Deutsche Dermatologie / Ausgabe 7/2022
Print ISSN: 2731-7692
Elektronische ISSN: 2731-7706
DOI
https://doi.org/10.1007/s15011-022-5023-x

Weitere Artikel der Ausgabe 7/2022

Deutsche Dermatologie 7/2022 Zur Ausgabe

Industrieforum

Nachrichten

Passend zum Thema

ANZEIGE

Die entscheidende Rolle des Mikrobioms bei atopischer Dermatitis

Bei atopischer Dermatitis besteht eine direkte Korrelation des Schweregrad der Erkrankung und einer verminderten Diversität des Mikrobioms. Studiendaten zeigen, dass durch eine Behandlung mit Emollienzien plus, die Besiedelung mit Staphylokokken reduziert und das Mikrobiom stabilisiert werden kann.

ANZEIGE

Welche Bedeutung hat das Mikrobiom bei Wundheilung und AD?

Warum hat das Mikrobiom der Haut in den letzten Jahren in der Wissenschaft an enormer Bedeutung gewonnen? Welche Möglichkeiten ergeben sich dadurch für die Behandlung bei Hautkrankheiten wie atopischer Dermatitis und der Wundheilung? Dies erläutert Prof. Thomas Luger im Interview.

ANZEIGE

Neueste Erkenntnisse zum Hautmikrobiom: vier Experten im Gespräch

Content Hub

Die Experten Prof. Luger (Münster), Prof. Zuberbier (Berlin), Prof. Thaçi (Lübeck) und PD Dr. Jansen (Essen) erörtern im von La Roche Posay unterstützen Expertenworkshop die Bedeutung des Mikrobioms für verschiedene Hautkrankheiten wie atopische Dermatitis, Akne oder Rosazea.

La Roche Posay